<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The WHO classification of <z:hpo ids='HP_0002665'>lymphomas</z:hpo> was established on the basis of clinical, morphological, immunohistochemical and genetic criteria </plain></SENT>
<SENT sid="1" pm="."><plain>However, each entity displays its own spectrum of clinical <z:hpo ids='HP_0000718'>aggressiveness</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Treatment success varies widely and is not predictable </plain></SENT>
<SENT sid="3" pm="."><plain>Since galectins are involved in <z:e sem="disease" ids="C1326912" disease_type="Neoplastic Process" abbrv="">oncogenesis</z:e> and the <z:mp ids='MP_0001532'>physiology</z:mp> of immune cells, we investigated whether galectin-1 and galectin-3 immunohistochemical expression could differ in 25 <z:mpath ids='MPATH_458'>normal</z:mpath> lymphoid tissues, 42 non-Hodgkins and 14 Hodgkins <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Immunohistochemical galectin expression was submitted to semi-quantitative and quantitative (computer-assisted microscopy) evaluations </plain></SENT>
<SENT sid="5" pm="."><plain>This study is completed by an analysis (by means of quantitative RT-PCR) of galectin-3 mRNA expression in 3 <z:mpath ids='MPATH_458'>normal</z:mpath> lymph nodes, 3 follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (FLs) and 3 diffuse large B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCLs</z:e>) </plain></SENT>
<SENT sid="6" pm="."><plain>The data show that in <z:mpath ids='MPATH_458'>normal</z:mpath> lymphoid tissue, lymphocytes do not express galectin-1 and rarely express galectin-3 </plain></SENT>
<SENT sid="7" pm="."><plain>In contrast, galectin-3 was expressed in 8 of the 16 DLBCL cases and in 1 of the 8 FL cases </plain></SENT>
<SENT sid="8" pm="."><plain>Furthermore, galectin-3 mRNA was expressed 3 times more in the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCLs</z:e> than in the FLs </plain></SENT>
<SENT sid="9" pm="."><plain>While the blood vessel walls of the <z:hpo ids='HP_0002665'>lymphomas</z:hpo> expressed galectin-1, the vessel walls of <z:mpath ids='MPATH_458'>normal</z:mpath> lymphoid tissues did not </plain></SENT>
<SENT sid="10" pm="."><plain>This expression of galectin-1 in blood vessel walls was correlated with vascular density </plain></SENT>
<SENT sid="11" pm="."><plain>The present study thus shows that <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> can be distinguished from <z:mpath ids='MPATH_458'>normal</z:mpath> lymphoid tissue and other <z:hpo ids='HP_0002665'>lymphomas</z:hpo> on the basis of galectin-3 expression </plain></SENT>
</text></document>